ESMO 2023 BioNTech Data

BNT211: CARVac cohort demonstrating a prolonged persistence of CAR-T cells Phase 1/2 FIH study (NCT04503278): Pharmacokinetic data Haanen J. et al. Presented at ESMO 2023. Abstract #LBA35. CLDN6 CAR -T Conc. (copies/µg) 106 105 104 103 102 101 1 x 108 (DL2) CAR-T only LLOQ 10° 0 25 GCT 50 EOC 75 100 25 Others Time (Day) 1 x 108 (DL2) CAR TCARVac LLOQ 50 50 75 100 ~D50 Conc. (copies/μg) ~D90 Conc. (copies/μg) 04 104 102 10⁰ 10-2 1 x 108 CAR-T only 1 x 108 CAR-T CARVac 104 04 102 100 10-2 1 x 108 CAR-T only 1 x 108 CAR-T CARVac Data cut-off: 1 Sep 2023. BioN Tech data on file derived from peripheral blood applying semi-quantitative PCR directed against CAR transgene. Displayed as copies of transgene per μg of DNA input of isolated PBMC. Pending data up to day 50: 2 patients each in monotherapy and combination cohort. Pending data up to day 90: 3 patients for monotherapy, and 4 patients for combination cohort. CAR = chimeric antigen receptor; CARVAC CAR T-cell amplifying RNA vaccine; DL = dose level; EOC = epithelial ovarian cancer; GCT = germ cell tumor; LLOQ = lower limit of quantification; PBMC = peripheral blood mononuclear cells. ESMO Congress 2023, Dr. John Haanen; Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. BIONTECH

View entire presentation